logo
Plus   Neg
Share
Email

Aldeyra Therapeutics Inc. (ALDX) Has Jumped To A New High On Study Results

Aldeyra Therapeutics Inc. (ALDX) announced Wednesday morning that its Phase 2b clinical trial of topical ocular reproxalap in patients with dry eye disease demonstrated statistically significant improvement across multiple symptom and sign measures.

Aldeyra Therapeutics has gapped open sharply higher this morning and is now up 2.65 at $12.55 on above average volume. The stock has leaped to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT
>